SEC Form 4 · accession 0001445064-15-000092
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mario D. Saltarelli
Officer — Sr. VP & Chief Science Ofcr.
Period of report
May 18, 2015
Accepted (ET)
May 19, 2015 · 5:25 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 18, 2015 | M | 3,912 | $0.00 | A | 11,388 | D | |
| Ordinary SharesF1 | May 18, 2015 | S | 4,580 | $127.44 | D | 6,808 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | $51.35 | May 18, 2015 | M | 3,912 | D | Jan 2, 2015 | Jan 2, 2024 | Ordinary Shares | 3,912 | 11,738 | D |
Explanation of responses
- F1This price represents a weighted average. The shares were sold at prices ranging from $127.43 to $127.46, inclusive. Mr. Saltarelli will provide, upon request of the SEC staff, Mallinckrodt plc, or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the ranges set forth in this Form 4.